The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis

There are a broad range of disease-modifying therapies (DMTs) available in relapsing-remitting multiple sclerosis (RRMS), but limited biomarkers exist to personalise DMT choice. All DMTs, including monoclonal antibodies such as rituximab and ocrelizumab, are effective in preventing relapses and pres...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neurotherapeutics
Main Authors: Zhong, Michael, van der Walt, Anneke, Campagna, Maria Pia, Stankovich, Jim, Butzkueven, Helmut, Jokubaitis, Vilija
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2020
Fag:
Current Perspectives
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851267/
https://ncbi.nlm.nih.gov/pubmed/33058021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-020-00950-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker